Latest & greatest articles for ranitidine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ranitidine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ranitidine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ranitidine

21. Meta-analyses of cisapride, omeprazole and ranitidine in the treatment of GORD: implications for treating patient subgroups

Meta-analyses of cisapride, omeprazole and ranitidine in the treatment of GORD: implications for treating patient subgroups Meta-analyses of cisapride, omeprazole and ranitidine in the treatment of GORD: implications for treating patient subgroups Meta-analyses of cisapride, omeprazole and ranitidine in the treatment of GORD: implications for treating patient subgroups Iskedjian M, Einarson T R Authors' objectives To examine the efficacy of the pharmocological treatment (...) of gastro-oesophageal reflux disease (GORD) with cisapride, omeprazole or ranitidine. Searching MEDLINE was searched from 1984 to 1995 using the following keywords: 'GERD' (gastroesophageal reflux disease), 'GORD', 'gastroesophageal', 'reflux', 'cisapride', 'ranitidine' and 'omeprazole'. The search was limited to studies in humans, but was not limited to articles published in the English language; articles in French, German and Italian were also included. The bibliographies of the retrieved articles and reviews located

DARE.1998

22. Ranitidine bismuth citrate in the treatment of Helicobacter pylori infection and duodenal ulcer

Ranitidine bismuth citrate in the treatment of Helicobacter pylori infection and duodenal ulcer Ranitidine bismuth citrate in the treatment of Helicobacter pylori infection and duodenal ulcer Ranitidine bismuth citrate in the treatment of Helicobacter pylori infection and duodenal ulcer Vondracek T G Authors' objectives To review the clinical pharmacology of ranitidine bismuth citrate (RBC)in the treatment of Helicobacter pylori (HP) infection and duodenal ulcer. Searching MEDLINE was searched (...) from 1992 to January 1997 for articles published in the English language, using the keywords 'Tritec', 'ranitidine' and 'bismuth'. References pertaining to the treatment of duodenal ulcers or HP were extensively searched for additional sources. Study selection Study designs of evaluations included in the review All articles pertaining to RBC were considered for inclusion. Emphasis was placed on randomised, double-blind trials. Priority was placed on data relating to regimes that were approved

DARE.1998

23. A cost-utility analysis comparing omeprazole with ranitidine in the maintenance therapy of peptic esophageal stricture

A cost-utility analysis comparing omeprazole with ranitidine in the maintenance therapy of peptic esophageal stricture A cost-utility analysis comparing omeprazole with ranitidine in the maintenance therapy of peptic esophageal stricture A cost-utility analysis comparing omeprazole with ranitidine in the maintenance therapy of peptic esophageal stricture Stal J M, Gregor J C, Preiksaitis H G, Reynolds R P Record Status This is a critical abstract of an economic evaluation that meets (...) data Effectiveness data were identified from a review of previously completed studies Modelling A decision tree model was used to determine the incremental cost utility of omeprazole compared with ranitidine over a one year period. Outcomes assessed in the review The probabilities of patients requiring redilation while receiving either omeprazole or ranitidine over a one year period, the risk of esophageal perforation during dilation or peptic stricture, the probability of surgery following

NHS Economic Evaluation Database.1998

24. A Comparison of Sucralfate and Ranitidine for the Prevention of Upper Gastrointestinal Bleeding in Patients Requiring Mechanical Ventilation

A Comparison of Sucralfate and Ranitidine for the Prevention of Upper Gastrointestinal Bleeding in Patients Requiring Mechanical Ventilation PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club1998

25. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. 9494148 1998 03 12 1998 03 12 2013 11 21 0028-4793 338 11 1998 Mar 12 The New England journal of medicine N. Engl. J. Med. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus (...) or 40 mg orally per day, or ranitidine, 150 mg orally twice a day, for four or eight weeks, depending on when treatment was successful (defined as the resolution of ulcer and the presence of fewer than five erosions in the stomach, and fewer than five erosions in the duodenum, and not more than mild dyspepsia). We randomly assigned 432 patients in whom treatment was successful to maintenance treatment with either 20 mg of omeprazole per day or 150 mg of ranitidine twice a day for six months

NEJM1998

26. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group.

A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. 9504939 1998 03 19 1998 03 19 2013 11 21 0028-4793 338 12 1998 Mar 19 The New England journal of medicine N. Engl. J. Med. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. 791-7 Critically (...) ill patients who require mechanical ventilation are at increased risk for gastrointestinal bleeding from stress ulcers. There are conflicting data on the effect of histamine H2-receptor antagonists and the cytoprotective agent sucralfate on rates of gastrointestinal bleeding, ventilator-associated pneumonia, and mortality. In a multicenter, randomized, blinded, placebo-controlled trial, we compared sucralfate with the H2-receptor antagonist ranitidine for the prevention of upper gastrointestinal

NEJM1998

27. A randomized controlled study of prophylactic Ranitidine in preventing stress-induced gastric mucosal lesions in neonatal intensive care unit patients.

A randomized controlled study of prophylactic Ranitidine in preventing stress-induced gastric mucosal lesions in neonatal intensive care unit patients. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club1997

28. [Cost-effectiveness comparison between omeprazole and ranitidine for treatment of reflux oesophagitis]

[Cost-effectiveness comparison between omeprazole and ranitidine for treatment of reflux oesophagitis] Comparaison des rapports cout-efficacite du traitement de l'oesophagite par reflux par omeprazole et ranitidine [Cost-effectiveness comparison between omeprazole and ranitidine for treatment of reflux oesophagitis] Comparaison des rapports cout-efficacite du traitement de l'oesophagite par reflux par omeprazole et ranitidine [Cost-effectiveness comparison between omeprazole and ranitidine (...) for treatment of reflux oesophagitis] Bergmann J F, Hamelin B, Barbier J P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Omeprazole versus ranitidine for the treatment of reflux oesophagitis. Type of intervention Treatment. Economic

NHS Economic Evaluation Database.1995

29. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer

Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer Poynard T, Lemaire M, Agostini H Authors' objectives To compare the clinical efficacy (...) of lansoprazole with the efficacies of ranitidine and famotidine. Searching The trials were identified using a MEDLINE search, a review of gastroenterology journals and from the files of two pharmaceutical companies (Houde and Takeda). Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were included. Specific interventions included in the review Lansoprazole at the usual dose of 30 mg compared with famotidine (4 0mg) or ranitidine (300 mg). Participants

DARE.1995

30. Long-term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole or ranitidine for healing of duodenal ulcer

Long-term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole or ranitidine for healing of duodenal ulcer Long-term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole or ranitidine for healing of duodenal ulcer Long-term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole or ranitidine for healing of duodenal ulcer Walan A, Eriksson S (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Treatment of duodenal ulcer with omeprazole or ranitidine. Type of intervention Treatment Economic study type Cost-effectiveness analysis Study population Hypothetical cohort

NHS Economic Evaluation Database.1994

31. A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer.

A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. 8284002 1994 02 17 1994 02 17 2013 11 21 0028-4793 330 6 1994 Feb 10 The New England journal of medicine N. Engl. J. Med. A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. 382-6 Hemorrhage is the most common complication of duodenal ulcer disease, but there is little information about the effectiveness and safety of long-term maintenance therapy (...) with histamine H2-receptor blockers. We conducted a double-blind study in patients with endoscopically documented hemorrhage from duodenal ulcers. Patients were randomly assigned to maintenance therapy with ranitidine (150 mg at night) or placebo and were followed for up to three years. Endoscopy was performed at base line (to document that the ulcers had healed), at exit from the study, and when a patient had persistent ulcer symptoms unrelieved by antacids or had gastrointestinal bleeding. Symptomatic

NEJM1994

32. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer.

Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. 8419816 1993 02 11 1993 02 11 2013 11 21 0028-4793 328 5 1993 Feb 04 The New England journal of medicine N. Engl. J. Med. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. 308-12 Persistent infection with Helicobacter pylori is associated with the recurrence of duodenal ulcer (...) placebos, given orally for 12 days. All patients also received ranitidine (300 mg each night) for 6 or 10 weeks. Endoscopy was performed before treatment and periodically during follow-up for up to 12 months after healing. Among the 52 patients given antibiotics, H. pylori was eradicated in 46, as compared with 1 of the 52 given placebo (89 percent vs. 2 percent, P < 0.001). After six weeks, the ulcers were healed in 48 patients given antibiotics and 39 given placebo (92 percent vs. 75 percent, P

NEJM1993

33. A randomized study of maintenance therapy with ranitidine to prevent the recurrence of duodenal ulcer.

A randomized study of maintenance therapy with ranitidine to prevent the recurrence of duodenal ulcer. 2651924 1989 05 26 1989 05 26 2013 11 21 0028-4793 320 17 1989 Apr 27 The New England journal of medicine N. Engl. J. Med. A randomized study of maintenance therapy with ranitidine to prevent the recurrence of duodenal ulcer. 1113-9 After an active duodenal ulcer has healed in response to medical therapy, the rate of recurrence during the subsequent year is relatively high. We therefore (...) enrolled 140 patients with healed duodenal ulcers in a two-year randomized, double-blind trial comparing maintenance therapy (ranitidine, 150 mg nightly) with placebo for the prevention of recurrent duodenal ulceration. We performed endoscopy annually and when symptoms suggested the recurrence of ulcers. Verified recurrent ulcers in either group were treated for four or eight weeks with open-label ranitidine (150 mg twice a day). Patients whose ulcers healed within eight weeks resumed randomized

NEJM1989

34. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine.

Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. 3142593 1989 01 12 1989 01 12 2013 11 21 0959-8138 297 6655 1988 Oct 22 BMJ (Clinical research ed.) BMJ Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. 1017-21 To evaluate the prophylactic effect of ranitidine 150 mg twice daily in patients requiring one of the following non-steroidal anti-inflammatory drugs (...) at baseline endoscopy (after one week without taking non-steroidal anti-inflammatory drugs). Those taking other antirheumatic agents, concomitant ulcerogenic drugs, or treatment for peptic ulcers within the previous 30 days were excluded. Age, sex, arthritic disease, and type of non-steroidal anti-inflammatory drug used were comparable in the two treatment groups. In all, 263 patients completed the trial. Ranitidine 150 mg twice daily or placebo (plus the selected non-steroidal anti-inflammatory drug

BMJ1988 Full Text: Link to full Text with Trip Pro

35. Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis.

Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis. 2890820 1987 12 22 1987 12 22 2015 06 16 0140-6736 2 8569 1987 Nov 21 Lancet (London, England) Lancet Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis. 1200-3 Sleeping with the bed-head raised is commonly recommended as treatment for patients with troublesome oesophagitis, but its effect has not been objectively tested. Ranitidine (...) with either treatment alone. Smoking more than five cigarettes per day or drinking more than 30 g alcohol per day significantly reduced the effectiveness of ranitidine therapy, but age, sex, body weight, or the presence of a hiatus hernia had no detectable effect. Harvey R F RF Gastroenterology Unit, Frenchay Hospital, Bristol. Gordon P C PC Hadley N N Long D E DE Gill T R TR Macpherson R I RI Beats B C BC Tottle A J AJ eng Clinical Trial Journal Article Randomized Controlled Trial England Lancet 2985213R

Lancet1987

36. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.

Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. 2880161 1987 03 16 1987 03 16 2015 06 16 0140-6736 1 8529 1987 Feb 14 Lancet (London, England) Lancet Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. 349-51 Omeprazole 60 mg once daily was compared with ranitidine 150 mg twice daily in an endoscopically-controlled, double-blind randomised trial in 51 outpatients with erosive (...) or ulcerative reflux oesophagitis (grade 2 or 3). Endoscopy was repeated after 4 weeks and, in the absence of healing, again after 8 weeks. Symptoms were assessed before entry and after 2, 4, and 8 weeks. Patients who were unhealed after 8 weeks were blindly switched to the other drug and treatment was continued for another 4 to 8 weeks. The healing rate (change to grade 0 or 1 oesophagitis) after 4 weeks was 19 of 25 patients treated with omeprazole and 7 of 26 patients treated with ranitidine (p = 0.002

Lancet1987

37. Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers.

Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. 2860494 1985 07 24 1985 07 24 2015 06 16 0140-6736 1 8441 1985 Jun 08 Lancet (London, England) Lancet Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. 1299-302 120 patients were randomly allocated to receive ranitidine 150 mg twice daily or a tri-potassium di-citrato bismuthate (TDB) tablet four times a day (...) in a trial comparing the effects of these drugs in the short-term healing and post-healing relapse rates of duodenal ulceration. At 4 weeks 81% of those on ranitidine and 90% of those on TDB had healed ulcer craters. At 8 weeks 97% of those on ranitidine and 97% of those on TDB had healed. These differences are not significant. After ulcer healing, the cumulative rates of relapse, as determined endoscopically, for symptomatic and symptomless ulcers were 74% for ranitidine and 41% for TDB at 4 months (p

Lancet1985

38. Ranitidine and cimetidine in prevention of duodenal ulcer relapse. A double-blind, randomised, multicentre, comparative trial.

Ranitidine and cimetidine in prevention of duodenal ulcer relapse. A double-blind, randomised, multicentre, comparative trial. 6147693 1984 10 25 1984 10 25 2015 06 16 0140-6736 2 8404 1984 Sep 22 Lancet (London, England) Lancet Ranitidine and cimetidine in prevention of duodenal ulcer relapse. A double-blind, randomised, multicentre, comparative trial. 659-62 In a comparative trial of preventive medication for duodenal ulceration with 51 participating centres, 484 patients were recruited (...) for a year's maintenance treatment with the recommended bedtime dose of ranitidine (150 mg; n = 243) or cimetidine (400 mg; n = 241). These outpatients had recently healed duodenal ulcers, confirmed by endoscopy before and after healing, and ulcer relapse was monitored by endoscopy every 4 months. The distribution of factors likely to influence ulcer recurrence was similar in the two treatment groups. A life-table method of analysis showed that the ulcer relapse rate was consistently and significantly

Lancet1984

39. Ranitidine 150 mg twice daily vs 300 mg nightly in treatment of duodenal ulcers.

Ranitidine 150 mg twice daily vs 300 mg nightly in treatment of duodenal ulcers. 6146821 1984 09 07 1984 09 07 2015 06 16 0140-6736 2 8397 1984 Aug 04 Lancet (London, England) Lancet Ranitidine 150 mg twice daily vs 300 mg nightly in treatment of duodenal ulcers. 274-6 102 patients with endoscopically proven duodenal ulcers were randomly allocated to treatment with ranitidine either 150 mg twice a day or 300 mg every evening for 4 weeks in a prospective double-blind study. The two groups were (...) similar. 48/57 (84%) healed on ranitidine 150 mg twice daily and 43/45 (96%) healed on 300 mg every evening (p = 0.9)--that is, ranitidine 300 mg as a single night time dose is as effective as 150 mg twice daily. The results also indicate the importance of overnight gastric acidity in the pathogenesis of duodenal ulcers. Ireland A A Colin-Jones D G DG Gear P P Golding P L PL Ramage J K JK Williams J G JG Leicester R J RJ Smith C L CL Ross G G Bamforth J J eng Clinical Trial Comparative Study Journal

Lancet1984